US FDA Approves sBLA of Pfizer for ABRILADA Interchangeability
The pharmaceutical company ‘Pfizer Inc.’ has now announced that, the US FDA has given approval for the reviewing the PAS (Prior Approval Supplement) to the BLA (Biologics License Application) for the ABRILADA as an interchangeable biosimilar to the Humira. Mike Gladstone, president of inflammation and immunology at Pfizer said, an interchangeability designation for the ABRILADA […]
Continue Reading